4-(对甲苯基)-4-羟基环己酮 | 36716-70-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(对甲苯基)-4-羟基环己酮
• 英文名称: 4-(p-Methylphenyl)-4-hydroxycyclohexanon
• 英文别名: 4-Hydroxy-4-p-tolyl-cyclohexanone；4-hydroxy-4-(4-methylphenyl)cyclohexan-1-one
• CAS: 36716-70-8
• 化学式: C₁₃H₁₆O₂
• 分子量: 204.269
• InChiKey: COHHDKBOPDVULP-UHFFFAOYSA-N

物化性质

• 沸点：
  366.0±42.0 °C(Predicted)
• 密度：
  1.142±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(对甲苯基)-4-羟基环己酮 在 吡啶 作用下， 反应 2.0h， 生成 4-(对甲苯基)-3-环己烯-1-胺
  参考文献：
  名称：

  联苯部分还原为中枢神经系统制剂。1. 4-芳基环己-3-烯胺。

  摘要：

  DOI：

  10.1021/jm00282a008
• 作为产物：
  描述：

  对甲苯基溴化镁 在 盐酸 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 反应 69.0h， 生成 4-(对甲苯基)-4-羟基环己酮
  参考文献：
  名称：

  Rh（I）的穿梭芳基化反应催化了未过滤醇的可逆碳-碳键活化

  摘要：

  转移氢化和借用氢反应的出现为以以前无法想象的方式操作简单的醇铺平了道路，并避免了对氢气的需求。类似地，转移烃基化可以大大提高叔醇的多功能性。然而，由于与未活化的CC键的催化裂解有关的挑战，该反应仍未得到探索。在本文中，我们报道了铑（I）催化的穿梭芳基化反应，通过氧化还原中性β-碳消除机制，在未应变的三芳基醇中裂解C（sp 2）-C（sp 3）键。使用良性醇作为潜在的C，实现了从叔醇到酮的取代（杂）芳基的选择性转移烃基化-亲核试剂。所有初步的机械实验都支持可逆的β-碳消除/迁移插入机制。在更广泛的背景下，这种新颖的反应性为催化叔醇的操作提供了新的平台。

  DOI：

  10.1016/j.chempr.2021.02.029

文献信息

• 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267689A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I): wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涵盖了以下式（I）的化合物： 其中：X，R1，R2，R3和R4如规范中所定义。该发明还涵盖了一种预防、治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病是II型糖尿病、肥胖和哮喘。该发明还涵盖了通过给哺乳动物施用至少一种式（I）化合物的治疗有效量来抑制CCR2活性的方法。
• 4'-Fluoro-4-{[4-(phenyl)-4-alkoxy-cyclo-hexyl]amino}butyrophenones and
  申请人：The Upjohn Company

  公开号：US03965180A1

  公开（公告）日：1976-06-22

  This invention relates to novel 4-(substituted alkoxy)-4-(substituted phenyl)cyclohexylamines embraced by the formula ##SPC1## Wherein .about. is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof, with the proviso that when the stereoconfiguration of the linkage connecting the cyclohexane ring and R.sup.3 O is is cis to the amino group, the linkage connecting the cyclohexane and phenyl rings is always trans, and vice versa; R is selected from the group consisting of lower alkyl of 1 through 4 carbon atoms, chlorine, fluorine, bromine, trifluoromethyl, and lower alkoxy of 1 through 4 carbon atoms; R' has the same meaning as R and in addition hydrogen; R.sup.1 is selected from the group consisting of hydrogen and lower alkyl of 1 through 4 carbon atoms; R.sup.2 is selected from the group consisting of hydrogen, lower alkyl of 1 through 4 carbon atoms, ring monosubstituted aroylalkyl wherein the substituents have the same meaning as R and R', above, aryl is from 6 through 10 carbon atoms and alkyl of from 1 through 4 carbon atoms and bis (ring monosubstituted)arylalkyl wherein the substituents have the same meaning as R and R', above, aryl is from 6 through 10 carbon atoms and alkyl of from 1 through 4 carbon atoms; R.sup.1 and R.sup.2 taken together with -N< is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and monosubstituted pyrrolidino, piperidino, hexamethyleneimino, morpholino and piperazino; R.sup.3 is lower alkyl of 1 through 4 carbon atoms; and an acid addition salt thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (1) and novel derivatives thereof. The systemic administration to humans and animals of the novel compounds (1) depresses their central nervous systems.

  这项发明涉及一种新型的4-(取代烷氧基)-4-(取代苯基)环己胺，其化学式为##SPC1##其中，.about.是一个通用表达式，表示顺式和反式立体构型及其混合物，但有一个条件，即当连接环己烷环和R.sup.3 O的连接的立体构型是顺式到氨基时，连接环己烷和苯环的连接总是反式，反之亦然；R选自由1至4个碳原子的低碳基、氯、氟、溴、三氟甲基和由1至4个碳原子组成的低烷氧基；R'与R具有相同的含义，另外还包括氢；R.sup.1选自由氢和由1至4个碳原子组成的低烷基；R.sup.2选自由氢、由1至4个碳原子组成的低烷基、环中单取代芳酰基烷基，其中取代基的含义与上述的R和R'相同，芳基由6至10个碳原子组成，烷基由1至4个碳原子组成，以及双(环中单取代)芳基烷基，其中取代基的含义与上述的R和R'相同，芳基由6至10个碳原子组成，烷基由1至4个碳原子组成；R.sup.1和R.sup.2连同-N<形成的饱和杂环氨基基团选自未取代和单取代的吡咯烷基、哌啶基、己亚甲基亚胺基、吗啉基和哌嗪基；R.sup.3是由1至4个碳原子组成的低烷基；以及其酸盐加合物。它还涉及上述新化合物(1)及其新衍生物的中间体和制备过程。将这些新化合物(1)系统地给人类和动物使用会抑制它们的中枢神经系统。
• 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2
  申请人：Zhang Xuqing

  公开号：US08513229B2

  公开（公告）日：2013-08-20

  The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涉及公式（I）的化合物：其中：X，R1，R2，R3和R4如规范中所定义。该发明还涉及一种预防、治疗或改善综合征、障碍或疾病的方法，其中所述综合征、障碍或疾病是2型糖尿病、肥胖症和哮喘。该发明还涉及一种通过给哺乳动物以公式（I）中至少一种化合物的治疗有效量来抑制CCR2活性的方法。
• Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2
  作者：Chu-Biao Xue、Anlai Wang、David Meloni、Ke Zhang、Ling Kong、Hao Feng、Joseph Glenn、Taisheng Huang、Yingxin Zhang、Ganfeng Cao、Rajan Anand、Changsheng Zheng、Michael Xia、Qi Han、D.J. Robinson、Lou Storace、Lixin Shao、Mei Li、Carrie M. Brodmerkel、Maryanne Covington、Peggy Scherle、Sharon Diamond、Swamy Yeleswaram、Kris Vaddi、Robert Newton、Greg Hollis、Steven Friedman、Brian Metcalf

  DOI：10.1016/j.bmcl.2010.10.020

  日期：2010.12

  Rational design based on a pharmacophore of CCR2 antagonists reported in the literature identified lead compound 9a with potent inhibitory activity against human CCR2 (hCCR2) but moderate activity against murine CCR2 (mCCR2). Modification on 9a led to the discovery of a potent CCR2 antagonist 21 (INCB3344) with IC(50) values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity. INCB3344 exhibited > 100-fold selectivity over other homologous chemokine receptors, a free fraction of 24% in human serum and 15% in mouse serum, and an oral bioavailability of 47% in mice, suitable as a tool compound for target validation in rodent models. (C) 2010 Elsevier Ltd. All rights reserved.
• Partly reduced biphenyls as central nervous system agents. 2. Cis- and trans-4-arylcyclohexylamines
  作者：Daniel Lednicer、D. Edward Emmert、Robert Lahti、Allan D. Rudzik

  DOI：10.1021/jm00282a009

  日期：1972.12